154 related articles for article (PubMed ID: 35728020)
1. Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline.
Rathmell WK; Rumble RB; Van Veldhuizen PJ; Al-Ahmadie H; Emamekhoo H; Hauke RJ; Louie AV; Milowsky MI; Molina AM; Rose TL; Siva S; Zaorsky NG; Zhang T; Qamar R; Kungel TM; Lewis B; Singer EA
J Clin Oncol; 2022 Sep; 40(25):2957-2995. PubMed ID: 35728020
[TBL] [Abstract][Full Text] [Related]
2. Tyrosine kinase and immune checkpoints inhibitors in favorable risk metastatic renal cell carcinoma: Trick or treat?
Catalano M; Procopio G; Sepe P; Santoni M; Sessa F; Villari D; Nesi G; Roviello G
Pharmacol Ther; 2023 Sep; 249():108499. PubMed ID: 37479037
[TBL] [Abstract][Full Text] [Related]
3. Advanced renal cell carcinoma management: the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG) consensus update.
Soares A; Monteiro FSM; da Trindade KM; Silva AGE; Cardoso APG; Sasse AD; Fay AP; Carneiro APCD; Alencar Junior AM; de Andrade Mota AC; Santucci B; da Motta Girardi D; Herchenhorn D; Araújo DV; Jardim DL; Bastos DA; Rosa DR; Schutz FA; Kater FR; da Silva Marinho F; Maluf FC; de Oliveira FNG; Vidigal F; Morbeck IAP; Rinck Júnior JA; Costa LAGA; Maia MCDF; Zereu M; Freitas MRP; Dias MSF; Tariki MS; Muniz P; Beato PMM; Lages PSM; Velho PI; de Carvalho RS; Mariano RC; de Araújo Cavallero SR; Oliveira TM; Souza VC; Smaletz O; de Cássio Zequi S
J Cancer Res Clin Oncol; 2024 Apr; 150(4):183. PubMed ID: 38594593
[TBL] [Abstract][Full Text] [Related]
4. Treatment Landscape of Renal Cell Carcinoma.
Chen YW; Wang L; Panian J; Dhanji S; Derweesh I; Rose B; Bagrodia A; McKay RR
Curr Treat Options Oncol; 2023 Dec; 24(12):1889-1916. PubMed ID: 38153686
[TBL] [Abstract][Full Text] [Related]
5. Managing Metastatic Renal Cell Carcinoma after Progression on Immunotherapy.
Barragan-Carrillo R; Govindarajan A; Rock A; Sperandio RC; Pal SK
Hematol Oncol Clin North Am; 2023 Oct; 37(5):965-976. PubMed ID: 37353376
[TBL] [Abstract][Full Text] [Related]
6. Managing First-Line Metastatic Renal Cell Carcinoma: Favorable-Risk Disease.
Pan E; Urman D; Malvar C; McKay RR
Hematol Oncol Clin North Am; 2023 Oct; 37(5):943-949. PubMed ID: 37258352
[TBL] [Abstract][Full Text] [Related]
7. [The Treatment of Metastatic Renal Cell Carcinoma: An Update].
Pezzicoli G; Ganini C; Re Sartò GV; Pirovano M; Cosmai L; Porta C
G Ital Nefrol; 2023 Oct; 40(Suppl 81):. PubMed ID: 38007832
[TBL] [Abstract][Full Text] [Related]
8. Trends of Utilization of Systemic Therapies for Metastatic Renal Cell Carcinoma in the Canadian Health Care System.
Cardenas LM; Ghosh S; Finelli A; Wood L; Kollmannsberger C; Basappa N; Graham J; Heng D; Bjarnason G; Soulières D; Bossé D; Castonguay V; Saleh R; Tanguay S; Bhindi B; Breau RH; Pouliot F; Lalani AA
JCO Glob Oncol; 2023 Sep; 9():e2300271. PubMed ID: 37992270
[TBL] [Abstract][Full Text] [Related]
9. Individualizing Systemic Therapies in First Line Treatment and beyond for Advanced Renal Cell Carcinoma.
Khan Y; Slattery TD; Pickering LM
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33322163
[TBL] [Abstract][Full Text] [Related]
10. ExPert ConsEnsus on the management of Advanced clear-cell RenaL celL carcinoma: INDIAn Perspective (PEARL-INDIA).
Sahoo TP; Desai C; Agarwal S; Rauthan A; Dhabhar B; Biswas G; Batra S; Saha R; Philip A; Agarwal V; Dattatreya PS; Mohapatra PN; Deshmukh C; Bhagat S; Patil S; Barkate H
BMC Cancer; 2023 Aug; 23(1):737. PubMed ID: 37558975
[TBL] [Abstract][Full Text] [Related]
11. Primary and acquired resistance to first-line therapy for clear cell renal cell carcinoma.
Astore S; Baciarello G; Cerbone L; Calabrò F
Cancer Drug Resist; 2023; 6(3):517-546. PubMed ID: 37842234
[TBL] [Abstract][Full Text] [Related]
12. Management of Metastatic Renal Clear Cell Cancer: ASCO Guideline Rapid Recommendation Update.
Singer EA; Rumble RB; Rathmell WK; Van Veldhuizen PJ;
J Clin Oncol; 2023 Nov; 41(33):5184-5186. PubMed ID: 37812756
[No Abstract] [Full Text] [Related]
13. ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma.
Powles T; Albiges L; Bex A; Grünwald V; Porta C; Procopio G; Schmidinger M; Suárez C; de Velasco G;
Ann Oncol; 2021 Dec; 32(12):1511-1519. PubMed ID: 34597799
[No Abstract] [Full Text] [Related]
14. Interleukin-2 in Renal Cell Carcinoma: A Has-Been or a Still-Viable Option?
Amin A; White RL
J Kidney Cancer VHL; 2014; 1(7):74-83. PubMed ID: 28326252
[TBL] [Abstract][Full Text] [Related]
15. Metastatic Renal Cell Cancer: Summary from ASCO 2015.
Can Urol Assoc J; 2015; 9(7-8):S158-61. PubMed ID: 26316916
[No Abstract] [Full Text] [Related]
16. Renal cell carcinoma: an overview of the epidemiology, diagnosis, and treatment.
Bahadoram S; Davoodi M; Hassanzadeh S; Bahadoram M; Barahman M; Mafakher L
G Ital Nefrol; 2022 Jun; 39(3):. PubMed ID: 35819037
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Powles T; Tomczak P; Park SH; Venugopal B; Ferguson T; Symeonides SN; Hajek J; Gurney H; Chang YH; Lee JL; Sarwar N; Thiery-Vuillemin A; Gross-Goupil M; Mahave M; Haas NB; Sawrycki P; Burgents JE; Xu L; Imai K; Quinn DI; Choueiri TK;
Lancet Oncol; 2022 Sep; 23(9):1133-1144. PubMed ID: 36055304
[TBL] [Abstract][Full Text] [Related]
18. Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma.
Choueiri TK; Powles T; Albiges L; Burotto M; Szczylik C; Zurawski B; Yanez Ruiz E; Maruzzo M; Suarez Zaizar A; Fein LE; Schutz FA; Heng DYC; Wang F; Mataveli F; Chang YL; van Kooten Losio M; Suarez C; Motzer RJ;
N Engl J Med; 2023 May; 388(19):1767-1778. PubMed ID: 37163623
[TBL] [Abstract][Full Text] [Related]
19. First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis.
Aldin A; Besiroglu B; Adams A; Monsef I; Piechotta V; Tomlinson E; Hornbach C; Dressen N; Goldkuhle M; Maisch P; Dahm P; Heidenreich A; Skoetz N
Cochrane Database Syst Rev; 2023 May; 5(5):CD013798. PubMed ID: 37146227
[TBL] [Abstract][Full Text] [Related]
20. Epidemiology of Renal Cell Carcinoma: 2022 Update.
Bukavina L; Bensalah K; Bray F; Carlo M; Challacombe B; Karam JA; Kassouf W; Mitchell T; Montironi R; O'Brien T; Panebianco V; Scelo G; Shuch B; van Poppel H; Blosser CD; Psutka SP
Eur Urol; 2022 Nov; 82(5):529-542. PubMed ID: 36100483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
